Taiwan's FDA Has Received 63 Suspected Adverse Reaction Reports on GLP-1 Injections This Year
Taiwan's Food and Drug Administration has received 63 suspected adverse reaction reports involving GLP-1 injections this year, 39 for weight-loss products and 24 for diabetes treatments, most often for gastrointestinal problems, low blood sugar, and nausea, with individual reports of intestinal obstruction and pancreatitis, Taiwan News reported on November 8, citing CNA. Ou Hong-yi, chair of the Taiwanese Association of Diabetes Educators, said the association is working with experts in Japan and South Korea on guidance for GLP-1 use around surgery, because slowed stomach emptying can leave food in the stomach even after fasting.